Journals / Troia Tıp Dergisi / 2021 / Cilt: 2 - Sayı: 2

Clinical management of chronic prostatitis/chronic pelvic pain syndrome: Literature review

Kronik prostatit/kronik pelvik ağrı sendromuna klinik yaklaşım: Literatür taraması

Pages
54–59
Publication Date
2021-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The multimodal approach to the treatment of the disease holds promise.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prostatitis; it is defined as the infection and edema of the prostate gland.
📊
Key Findings & Data:It can affect men of all age groups and has a significant impact on patients' quality of life.
💡
Conclusion & Impact:The multimodal approach to the treatment of the disease holds promise.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Prostatit · pelvik ağrı · tanı

Abstract

Prostatitis; it is defined as the infection and edema of the prostate gland. It may be accompanied by pelvic pain, discomfort, voiding and ejaculation dysfunction. It can affect men of all age groups and has a significant impact on patients' quality of life. It is divided into four groups according to the classification system established by the National Institutes of Health for prostatitis. These groups are; acute bacterial prostatitis (group 1), chronic bacterial prostatitis (group 2), chronic prostatitis/chronic pelvic pain syndrome (inflammatory: group 3A, non-inflammatory: group 3B) and asymptomatic prostatitis (group 4). Chronic prostatitis/chronic pelvic pain syndrome group constitutes >90% of all patients with prostatitis-like complaints. This definition represents a heterogeneous patient group and is an exclusion diagnosis. Many different types of treatment have been used for chronic prostatitis/chronic pelvic pain syndrome, such as antibiotics, anti-inflammatories, alpha blockers, hormonal treatments, neuromodulatory treatments, herbal treatments, physical therapies, acupuncture treatments. However, it has been shown that monotherapies are not effective enough. The multimodal approach to the treatment of the disease holds promise.

Özet

Prostatit; prostat bezinin enfekte olması ve ödemlenmesi olarak tanımlanır. Pelvik ağrı, rahatsızlık, işeme ve boşalma semptomları eşlik edebilir. Her yaş grubundan erkeği etkileyebilir ve hastaların yaşam kalitesi üzerinde önemli etkileri vardır. Ulusal Sağlık Enstitüleri’nin (National Institutes of Health) prostatit için oluşturduğu sınıflama sistemine göre dört gruba ayrılır. Bunlar; akut bakteriyel prostatit (grup 1), kronik bakteriyel prostatit (grup 2), kronik prostatit/kronik pelvik ağrı sendromu (inflamatuvar: grup 3A, non-inflamatuvar: grup 3B) ve asemptomatik prostatittir (grup 4). Prostatit benzeri şikayetleri olan hastaların >%90’ını kronik prostatit/kronik pelvik ağrı sendromu grubu oluşturur. Bu tanım heterojen bir hasta grubunu temsil eder ve bir dışlama tanısıdır. Tedavisinde antibiyotikler, anti-inflamatuvarlar, alfa blokerler, hormonal tedaviler, nöromodülatör tedaviler, bitkisel tedaviler, fizik tedaviler, akupunktur tedavileri gibi çok farklı tedavi çeşitleri uygulanmış ancak monoterapilerin yeterince etkinlik sağlamadığı gösterilmiştir. Hastalığın tedavisinde multimodal yaklaşım umut vadetmektedir.

🔖

Cite This Article

ÜNAL, S., ÇULHA, M. G. (2021). Clinical management of chronic prostatitis/chronic pelvic pain syndrome: Literature review. Troia Tıp Dergisi, Cilt: 2 - Sayı: 2, 54–59. https://ajindex.com/articles/415710

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Clemens JQ, Stephens-Shields AJ, Newcomb C, et al. Correlates of 1-year change in quality of life in patients with urologic chronic pelvic pain syndrome: Findings from the multidisciplinary approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. J Urol. 2020;204(4):754-9
  2. Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Kimes T, Calhoun EA. Prevalence of and risk factors for prostatitis: Population based assessment using physician assigned diagnoses. J Urol 2007;178(4 Pt 1):1333-7
  3. Krieger JN, Nyberg L, Jr., Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282(3):236-7
  4. Schaeffer AJ, Landis JR, Knauss JS, et al. Demographic and clinical characteristics of men with chronic prostatitis: The national institutes of health chronic prostatitis cohort study. J Urol 2002;168(2):593-8
  5. Nickel JC, Shoskes DA, Wagenlehner FM. Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): The studies, the evidence, and the impact. World J Urol 2013;31(4):747-53
  6. Krieger JN, Lee SW, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents 2008;31 Suppl 1:S85-90
  7. Wagenlehner FM, van Till JW, Magri V, et al. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2013;63(5):953-9
  8. Propert KJ, Litwin MS, Wang Y, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006;15(2):299-305
  9. Badía X, García-Losa M, Dal-Ré R. Ten-language translation and harmonization of the International Prostate Symptom Score: Developing a methodology for multinational clinical trials. Eur Urol 1997;31(2):129-40
  10. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822-30
  11. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968;5(5):492-518
  12. Engeler D, Berghmans B, Borovicka J, et al. EAU Guidelines on Chronic Pelvic Pain. European Association of Urology Guidelines, presented at the EAU Annual Congress Amsterdam 2020, ISBN978-94-92671-07-3
  13. Bonkat G, Bruyère F, Cai T, et al. EAU Guidelines on Urological Infections. European Association of Urology Guidelines, presented at the EAU Annual Congress Milan Italy 2021, I